Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.34 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12424332 | 0.81 | APLNR (0.39) | CYP2C19CYP1A2CYP2D6ALOX15SLC1A3 | |
| SCHEMBL12384655 | 0.81 | APLNR (0.39) | CYP2C19CYP1A2CYP2D6ALOX15SLC1A3 | |
| SCHEMBL1769081 | 0.79 | APLNR (0.37) | CYP2C19CYP1A2CYP2D6ALOX15SLC1A3 | |
| SCHEMBL864032 | 0.79 | APLNR (0.37) | CYP2C19CYP1A2CYP2D6ALOX15SLC1A3 | |
| SCHEMBL1073419 | 0.76 | GLA (0.43) | APLNRGLABTKLMNAGRM2 | |
| SCHEMBL20047617 | 0.72 | BTK (0.49) | GLABTKLMNAGRM2GABRR1 | |
| SCHEMBL14436576 | 0.72 | BTK (0.49) | GLABTKLMNAGRM2GABRR1 | |
| SCHEMBL863425 | 0.72 | BTK (0.49) | GLABTKLMNAGRM2GABRR1 | |
| SCHEMBL17803093 | 0.70 | CES2 (0.37) | CYP2C19CYP1A2CYP2D6ALOX15SLC1A3 | |
| SCHEMBL1835961 | 0.70 | GLA (0.50) | CYP2D6APLNRGLALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9637516-B2 | Betulinic acid proline derivatives as HIV inhibitors | HETERO RESEARCH FOUNDATION (IN) | 2017-05-02 | — | — | US | disclosed |
| US-20150337004-A1 | NOVEL BETULINIC ACID PROLINE DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2015-11-26 | — | — | US | disclosed |
| US-20150119373-A1 | NOVEL BETULINIC ACID DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119373-A1 | NOVEL BETULINIC ACID DERIVATIVES AS HIV INHIBITORS | BET1, PGGT1B, RABGGTB | CYP2C19 3280/4885CYP1A2 3068/4885CYP2D6 3427/4885 |
| US-20150337004-A1 | NOVEL BETULINIC ACID PROLINE DERIVATIVES AS HIV INHIBITORS | BET1, PRR12, PELP1 | CYP2C19 3597/4885CYP1A2 4049/4885CYP2D6 3924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.